Feature Fusion of Raman Chemical Imaging and Digital Histopathology using Machine Learning for Prostate Cancer Detection

Trevor Doherty, Susan McKeever, Nebras Al-Attar, Tiarnán Murphy, Claudia Aura, Arman Rahman, Amanda O’Neill, Stephen P Finn, Elaine Kay, William M. Gallagher, R. William G. Watson, Aoife Gowen & Patrick Jackman

The diagnosis of prostate cancer is challenging due to the heterogeneity of its presentations, leading to the over diagnosis and treatment of non-clinically important disease. Accurate diagnosis can directly benefit a patient’s quality of life and prognosis. Towards addressing this issue, we present a learning model for the automatic identification of prostate cancer. While many prostate cancer studies have adopted Raman spectroscopy approaches, none have utilised the combination of Raman Chemical Imaging (RCI) and other imaging modalities. This study uses multimodal images formed from stained Digital Histopathology (DP) and unstained RCI. The approach was developed and tested on a set of 178 clinical samples from 32 patients, containing a range of non-cancerous, Gleason grade 3 (G3) and grade 4 (G4) tissue microarray samples. For each histological sample, there is a pathologist labelled DP - RCI image pair. The hypothesis tested was whether multimodal image models can outperform single modality baseline models in terms of diagnostic accuracy. Binary non-cancer/cancer models and the more challenging G3/G4 differentiation were investigated. Regarding G3/G4 classification, the multimodal approach achieved a sensitivity of 73.8% and specificity of 88.1% while the baseline DP model showed a sensitivity and specificity of 54.1% and 84.7% respectively. The multimodal approach demonstrated a statistically significant 12.7% AUC advantage over the baseline with a value of 85.8% compared to 73.1%, also outperforming models based solely on RCI and median Raman spectra. Feature fusion of DP and RCI does not improve the more trivial task of tumour identification but does deliver an observed advantage in G3/G4 discrimination. Building on these promising findings, future work could include the acquisition of larger datasets for enhanced model generalization.

1 Introduction
Cancer is a primary cause of morbidity and mortality worldwide with prostate cancer having the second highest incidence of can-

cer among men. It is estimated that prostate cancer will account for 33,330 deaths and 191,930 new cases in the U.S. in 2020. Manual histologic assessment of prostate tissue biopsies by a pathologist constitutes the definitive diagnosis of prostate cancer. Pathologists utilize advanced imaging techniques and biomarker discovery through the use of Haematoxylin and Eosin (H&E) to visually analyze the morphological features within a prostate tissue sample and use the Gleason grading system to identify nonmalignant, benign hypertrophic and malignant prostatic tissues. Limitations of this staining process including reactivity to staining agents from different manufacturers, tissues’ thickness, stain concentration, batch effects, room temperature during preparation and alteration of the applied method lead to staining variation across use cases. This, in addition to factors such as the extent of a pathologist’s skill and training in Gleason grading, weariness due to the laborious assessment procedure and subjectivity introduce error into the pathologist report and
Fundamental differences in the molecular expression of a range of diseases including some cancers tend to present themselves as changes in tissue architecture and nuclear morphology. As a result, there has been significant interest in the use of digital pathology to develop algorithms and feature extraction methods for the automatic classification of tissue types, the grading of disease and prediction of disease prognosis. In addition to digital pathology, spectroscopic methods are highly suitable for the in situ observation of molecular changes, allowing characterization of complex biological systems. By interrogating chemical content, Raman scattering can produce a detailed fingerprint of a material. Raman spectroscopy as the most dominant spectral technique has shown details of molecular information with the ability to provide qualitative and quantitative biochemical signatures in addition to sample morphology. Furthermore, Raman spectroscopy can simultaneously identify and detect a variety of molecular structures such as proteins, DNA, RNA, and lipids in a single acquisition. Chemically complex milieux of biological samples revealed by Raman spectroscopy allow investigation of functional groups, bonding types and molecular conformations and have led to markers for cancer detection. Consequently, Raman spectroscopy has been applied to a range of cancer modalities such as colon, breast, lung, cervix and prostate among others.

Prostate adenocarcinoma has shown to be difficult to accurately characterize, partially due to histological heterogeneity of samples. This characteristic heterogeneity is more suited to an approach based on image analysis as opposed to ‘point’ spectroscopy. Kast et al. suggested that an opportunity exists to combine the power of Raman spectroscopy with imaging technologies as this would allow correlation of sample morphology with molecular information. Raman chemical imaging (RCI) is a novel emerging approach that utilises conventional Raman spectroscopy with a spatial mapping process that results in a detailed chemical map of the sample containing biochemical information that is imperceptible by conventional methods. Utilising RCI, Samiei et al. found that it showed promise as a technique in the identification of patients who were at risk of post-radical prostatectomy progression, indicating distinctive chemical differences in biochemical failure Gleason 7 patients, while Tollefson et al. observed distinctive chemical differences between prostate tissue for patients that progressed to metastatic disease and those that didn’t.

While many prostate cancer studies in the current literature utilise Raman spectroscopy-based approaches, none have explored the combination of RCI with other imaging modalities. RCI applied to the identification of cancer biomarkers in prostate tissue could lead to improvements in current identification processes by complementing traditional staining methods. Image fusion methods incorporating multi-sensor and multi-source data offer a wider diversity of potential features for medical analysis applications. Adopting a multimodal microscopy approach for the automated analysis of prostate cancer, Kwak et al. combined imaging data from Fourier transform infra-red and optical microscopy and achieved better accuracy on the fusion of these data sources than a single data source alone. The combination of coherent anti-Stokes Raman scattering, two-photon excited fluorescence and second harmonic generation microscopy showed promise in differentiation of head and neck cancers and non-cancerous epithelium while Patil et al. demonstrated that the integration of Raman spectroscopy with Optical Coherence Tomography (OCT) enhanced the detection of ex-vivo breast cancer when compared with either approach alone. Investigating colon adenocarcinoma, Ashok et al. used Raman spectroscopy and OCT which individually yielded sensitivities of 89% and 77% respectively and specificities of 78% and 74% respectively. Both sensitivity and specificity improved to 94% for the combined imaging model. Yuan et al. devised a predictor for breast cancer survival that combined both image and gene expression analyses that significantly outperformed models that used only a single data source. This study proposes the development of a multimodal machine learning model that integrates features from both digital histopathology and RCI.

Many approaches extract quantitative morphological information from histopathology sample images. For the automatic Gleason grading of prostate cancer, Nguyen et al. extracted morphological and phase based features relating to glands and surrounding stroma to predict disease pathology. Lee et al. utilised domain inspired features for the prediction of biochemical recurrence of prostate cancer, while, in a study on male breast cancer, Veta et al. found mean nuclear area to be a significant prognostic indicator. Doyle et al. utilised architectural and textural features to achieve an accuracy of 76.9% for the classification of Gleason grade 3 and 4 histological tissue patches. Novel explicit shape descriptors have been used to differentiate between intermediate Gleason grade (grades 3 and 4) prostate glands using histopathology images with an accuracy of 89% and AUC of 0.78 being reported. Linder et al. utilised local binary patterns for the segmentation of tumour stromal and epithelial regions using bright field microscopy for colorectal cancer. Jafari-Khouzani and Soltanian-Zadeh utilized energy and entropy features of multiwavelet coefficients in order to classify prostate cancer Gleason scores from optical microscopy images. Sanghavi et al. adopted Speeded Up Robust Features (SURF) and Scale Invariant Feature Transform (SIFT) with Bag of Visual Words (BoVW) to identify prostate cancer grades from histopathology images.

SIFT is a feature detection algorithm from the field of computer vision which locates and describes distinctive invariant image features. Clustering of feature vectors yields cluster centroids that characterize visual words. Pretrained dictionaries can be used to map descriptors within new images to the closest visual word. An image can then be represented as a histogram of its component visual words, generating an input vector for a classification algorithm. Deep learning and transfer learning have shown efficacy when applied to the analysis and classification of cancer and other diseases. A drawback of deep learning is that it requires large amounts of training data, which is not commonly the case in the medical domain. Several studies have demonstrated promise on prostate cancer detection using deep learning, how-

2 | Journal Name, [year], [vol.], 1-10
ever these studies have utilised relatively large patient cohorts and image sets. Ishioka, Arvanit, Litjens, and Song studies contained 335, 886, 225 and 195 patients respectively. Where large numbers of samples are not available and deep learning is not applicable, well established computer vision techniques such as SIFT come into play. Wang et al. chose the SIFT image feature with bag-of-word model as the non-deep learning representative method in their comparison of deep-learning versus non-deep learning for the classification of prostate cancer using MRI images. SIFT with BoVW was one of the main representative methods for computer aided diagnosis algorithms before the era of deep learning as can be seen in the results of ImageNet 2012. It is, therefore, still a valuable approach when dataset size precludes the use of deep learning technology and is used in this study.

The current study which developed models that classify prostate tissue samples goes beyond existing studies by integrating features of both Raman chemical and histopathology images. The main research question was whether models trained on multimodal images can classify prostate cancer tissue samples more effectively than a range of single modality baseline models utilizing digital histopathology imaging, Raman chemical imaging or median Raman spectra. Specifically, the study aimed to investigate these approaches through the binary classifications of cancer/non-cancer and Gleason grade 3/ grade 4 tissue samples with the latter case relating to the much more challenging and clinically relevant assessment of cancer severity. This research constitutes an initial evaluation of the approach with more data being necessary for a generalizable model.

2 Materials and Methods

2.1 Histopathology sample preparation Raman Mapping

A formalin fixed paraffin embedded prostate tissue microarray (TMA) of 32 patients was obtained from the Irish Prostate Cancer Research Consortium (PCRC) with ethical approval and patient written consent. This TMA set consists of three TMA blocks comprising 178 cores. The TMA sections were cut and placed on a standard microscopic slide. The optimal tissue thickness was investigated through employing various block cut thicknesses (4,8,10, and 16 µm) A 10 µm TMA thickness was the optimal choice for Raman imaging as it provided spectra that were relatively free of interference from the substrate. Additionally, this thickness allowed a sufficient layer of tissue to include features such as epithelial cells, stroma, fibroblast, and red blood cells.

Samples were then baked in the oven at 60°C for one hour and allowed to dry. A de-paraffinization protocol was introduced to effectively remove paraffin from the tissue sections, described as follows: samples were consecutively dewaxed in three baths of xylene for 6 minutes each followed by three baths of graded ethanol (100%, 90%, and 80%), also for 6 minutes each. The samples were rehydrated by immersing them in deionized water for 6 minutes. The rehydrated tissues were then kept in deionized water in petri dishes in advance of Raman imaging tissue spectral acquisition. Rehydrated samples were imaged on standard glass slides under water immersion. After Raman imaging tissue samples were manually stained with Haematoxylin-Eosin.

Raman imaging spectroscopy was performed using a Renishaw inVia Micro-Raman confocal spectroscopy system (Renishaw, Wotton-under-Edge, Gloucestershire, UK) fitted with a 532nm and 785nm solid-state diode laser. The 532nm laser was selected to perform Raman Imaging. Raman spectra were recorded using water immersion x63 objective and a grating (600 line/mm) with a 1 second acquisition time. Before spectral data was gathered a brightfield montage of the entire slide was collected in order to assist in targeting the TMA cores and minimise the amount of data collected from empty sections of the slide. Experiments could then be queued to run consecutively. Multiple single point scans were used to perform map image acquisition. A rectangular grid was created to sample the core surface using WiRE software version 4.1. The dimensions of the grid step size were 33µm in the x direction and 33µm in the y direction. The total mapped area varied according to the slight variability in TMA core size, ranging from 19x31 pixels to 48x37 pixels.

2.2 TMA digitization

Hematoxylin solution modified acc. to Gill II and Eosin Y-solution 0.5% aqueous were purchased from Sigma-Aldrich to perform staining on the PCRC Cohort after completion of Raman acquisition. H&E staining was performed in one batch using routine clinical protocols. H&E slides were cover-slipping and digitized at 20x magnification using a whole slide scanner (Aperio ScanScope CS, Leica Biosystems, Buffalo Grove, IL, United States). For cross-validation of Gleason score (GS), the digitized H&E TMA images were investigated at the core-level by histopathology. These images were annotated corresponding to the TMA map core description using Oncotpix (from Visiopharm) Version 2019.07 platform. Hence, the TMA map was loaded to the Visiopharm platform to obtain TIFF format images for individual cores which correspond to patient ID. This allows the pathologist to validate the H&E staining, GS crosscheck, and annotate the tumours for individual cores. Meantime, the cores containing artifacts of the histological processing (e.g., tissue folds, debris), were demarcated using the same tools. These cores were ultimately excluded from Raman Imaging data. Digitized cores and their annotations were stored and managed.

2.3 Patient Cohort and Sample Details

To investigate the effect of augmenting digital pathology images with RCI, a study was conducted on a cohort of 32 prostate cancer patients. 178 TMA samples were obtained as multiple samples could be extracted from a single patient’s radical prostatectomy tissue. Cancer TMA samples were pathologically confirmed normal, Gleason grade 3 or 4, as according to the paper by Breen et al. Raman chemical images of the samples were acquired with the pathologically verified label being transferred from the digital pathology sample to its Raman counterpart. Table 1 outlines the data summary and class distribution of non-cancer, Gleason grade 3 and grade 4 samples.
### Table 1: Class balance details for 32-patient cohort

| Class          | No. of Digital Pathology Images | No. of Raman Chemical Images | % of Total Samples |
|----------------|---------------------------------|------------------------------|--------------------|
| Non-cancer     | 82                              | 82                           | 45.8%              |
| Cancer         | 97                              | 97                           | 54.2%              |
| **Total**      | **179**                         | **179**                      | **100.0%**         |

| Cancer Breakdown | No. of Digital Pathology Images | No. of Raman Chemical Images | % of Total Samples |
|------------------|---------------------------------|------------------------------|--------------------|
| Gleason 3        | 51                              | 51                           | 52.6%              |
| Gleason 4        | 45                              | 45                           | 46.3%              |
| Gleason 5        | 1                               | 1                            | 1.0%               |
| **Total**        | **97**                          | **97**                       | **100.0%**         |

### 2.4 Image pre-processing

Pretreatment of Raman spectra included the removal of saturated pixels followed by cosmic ray correction using in-house functions in MATLAB 2019a. Spectra were used to form Raman chemical images with each spectrum constituting a single pixel of a tissue sample image. Each TMA sample’s Raman chemical image was approximately 33 x 33 pixels. The mean of each pixel’s spectrum was used to form a grey scale 2-D Raman chemical image. The Raman chemical images were then upsampled to 500 x 500 pixels using cubic spline interpolation. Up-sampling better facilitated the discovery of useful local and global features before input to the SIFT feature detection algorithm.

Colour optical microscopy (digital pathology) images (approximately 1500 x 1500 pixels) were converted to greyscale via the Python OpenCV package which implements the conversion function:

\[ Y = 0.299R + 0.587G + 0.114B \]

where R, G and B represent the red, green and blue channel intensity values. The greyscale digital pathology images were then downsampled to match the resolution of the corresponding 500 x 500 Raman images.

**Fig. 1** Two Gleason grade 4 samples ((a) and (b)) and a non-cancer sample (c). Colour digital histopathology images are shown in (a) to (c) with corresponding Raman images in (d) to (f).

Visually, the upscaled greyscale Raman chemical images have low contrast values i.e. most of the pixel intensity values exist in a relatively narrow range per image. As a means of contrast stretch-

### 2.5 Image-based model configurations

Two binary classification tasks (non-cancer/cancer and Gleason grade 3/grade 4) were investigated for three imaging configurations. The first configuration was digital histopathology (optical microscopy), the second utilised RCI and the third was a combination of digital histopathology and RCI. Five-fold cross validation with each fold containing samples from disjoint sets of patients was investigated i.e patient sample independence was ensured. The feature extraction approach used in this study first partitions images into reference and classification sets. Reference images were used to form image features which then encode the classification set. 179 images were used for the binary non-cancer/cancer task - 52 reference images for defining the image features and 127 for building the classification models. 96 images were used for the Gleason grade 3/grade 4 task – 27 reference images and 69 images for the classification models. Both binary classification tasks were evaluated using a single reference and classification partition. On witnessing promising results for the task of Gleason grade 3/ grade 4 differentiation, modelling was extended to incorporate 10 different reference/classification partitions (average performance metrics over the 10 models were reported). This amounted to 9 model configurations in total. Table S3 in the Supplementary Material gives an overview of the models investigated.

### 2.6 Models with Single & Multiple Reference Sets

SIFT feature encoding of the classification sets for models 1-6 in Table S3 were based on a single reference set. Reference sets were formed from samples belonging to a randomly selected set of patients. These patients and their samples were not used in the classification sets. The reference set of images were used to encode the remaining images (using the technique explained in the Feature Extraction section). These remaining images consti-
tuted the classification set and were used for model training and evaluation via cross-validation. Cross-validation was structured such that samples from 5 disjoint sets of patients were used in each fold - this ensured patient independence across folds.

For models 7-9 in Table S3, 10 separate models based on differing reference/classification partitions were generated. Mean cross-validation performance scores were generated for each of the 10 models with the overall average of these individual means reported. As described above, the same approach to patient independence across the reference sets and cross-validation folds was followed.

### 2.7 Reference - Classification Sets and Dictionary Sizes

The aforementioned reference sets were used to form dictionaries of visual words for each model. Table 2 shows the breakdown of images used for both the reference and classification sets for each diagnostic classifier and pathological class (single reference set case).

| Table 2 Reference and Classification Set Image Distribution |
|-----------------------------------------------------------|
| Set | Diagnostic Model | Normal | G3 | G4 | G5 | Total |
| Reference | Non-cancer/Cancer | 23 | 16 | 12 | 1 | 52 |
| | Gleason 3/4 | 12 | 15 | 27 | |
| Classification | Non-cancer/Cancer | 59 | 35 | 33 | | 127 |
| | Gleason 3/4 | 39 | 30 | | | 69 |

The dictionary size parameter was optimized in a similar fashion to the optimisation of the support vector machine (SVM) hyperparameters. For the single imaging approach of digital histopathology, image histograms were generated and passed to the classification stage over a range of investigated dictionary sizes. These were [50, 75, 100, 200, 300, 500, 1000], which represent the number of visual words that were generated via the BoVW clustering stage and thus the visual words used to encode an image as a histogram of visual word frequencies. In the case of the RCI single imaging approach, the dictionary sizes used were [5, 10, 25, 50, 100, 200, 300]. For the multimodal approach, the range of dictionaries investigated were combinations of the values used for both single imaging approaches i.e. [50, 75, 100, 200, 300, 500, 1000] and [5, 10, 25, 50, 100, 200, 300] for the digital pathology and Raman imaging models respectively. Image histograms of visual words were generated for each value in the tested ranges with permutations of these being used to optimise each model.

### 2.8 Feature Extraction

Scale Invariant Feature Transform (SIFT) was used to extract image features. SIFT is an image descriptor that can be used for image recognition. The descriptor shows invariance to scaling, rotation and translation in the image domain and exhibits robustness to moderate illumination variation and perspective transforms. The SIFT descriptor has been shown to be effective in practice for real-world object recognition. It utilizes a method that detects points of interest from grey-level images. Statistics relating to local gradient directions of image intensities are collected which give a description of local image structures in an interest point’s local neighbourhood. Figure 3 outlines the SIFT detection and description process. The results of Scale Invariant Feature Transform yield high-dimensional feature vectors, each describing a single key point. Exhaustive matching of key point descriptors across images can be avoided by utilizing the classic bag-of-words paradigm from the field of information retrieval. The key point descriptors extracted by the SIFT algorithm are grouped into clusters with each cluster containing similar descriptors. Each cluster can be treated as a visual word that represents certain local patterns which are common among the descriptors in that cluster. The combination of these clusters yields a visual word vocabulary that describes a range of local image patterns. This mapping of key points to visual words represents a dictionary that can be used to represent the image as a bag of visual words.

This equates to a vector containing the visual word count which can then be used at the classification stage. In the case of the combined digital pathology and Raman imaging models, the feature vectors extracted from each modality were concatenated to form a single representation of the image pair for a tissue microarray sample. For the single modality cases, just the feature vector derived from the digital pathology or Raman chemical image was utilized. Figure 4 shows the main stages of the Bag of Visual Words approach.

The main steps outlined in Figure 4 involve:

(a) The reference images are decomposed into many SIFT features. By K-Means clustering, these SIFT features are clustered to a predefined number of clusters. The centroids of these clusters are referred to as visual words. In this example, three visual
words are generated. The set containing all the visual words is referred to as a dictionary e.g. 27 reference images were used to build a visual word dictionary for the Gleason grade 3/4 classification model.

(b) Given a new image to be represented by a bag-of-words model, it is first decomposed into several SIFT features. Each SIFT feature is assigned to the nearest visual word using Euclidean distance i.e. vector quantization. Implementing such feature assignment for each SIFT feature, the image can be represented as a histogram of visual word frequencies i.e. the counts of the occurrences of the SIFT features assigned to each visual word.[73]

For the Gleason grade 3/4 classifier, 69 images were converted to visual word histograms based on the dictionary formed by the 27 reference images. These 69 images were then used to build a cross-validated classification model. The same process was applied for histopathology images.

2.9 Image Histogram Visualisation

The process of SIFT feature extraction and BoVW clustering yields image representations in the form of histograms of visual words. These frequency distributions detail how many of each type of feature (visual word) occurs in a given image. Fig. 5 shows examples of normal and cancer tissue sample BoVW image histograms for H&E and Raman chemical imaging. Similarly, for the cases of Gleason grade 3 and 4, Fig. 6 contains examples of tissue sample BoVW image histograms pertaining to both image modalities.

2.10 Image Feature Representations for Classification

The histogram image representations generated in the feature extraction step are then passed to a classification algorithm. In the case of the combined digital pathology/RCI models, the feature vectors extracted from each modality were concatenated to form a single representation of the image pair for a tissue microarray sample. With the images converted to vector representations (histograms), a support vector machine was utilized to learn from training images and classify test images. Based on these image
representations, the classifier outputs probability-like values that a tissue sample belongs to a given class.

Five-fold cross validation was used to assess the efficacy of models. This is a robust approach which partitions images into 5 approximately equal sized folds. Given that there were multiple sample images per patient, the folds of the cross-validation were formed from 5 disjoint sets of patient sample images. This approach ensures the independence of the training and test data sets within the cross-validation process. The overall algorithmic process is outlined in Figure 7.

2.11 Classification with Support Vector Machines

For the application of the SVM, the software package sklearn.svm from Python was used (version sklearn==0.0). This involved implementation of the SVC (support vector classification) class which is based on libsvm. Two kinds of kernel functions were compared i.e. linear and radial basis function (RBF) in each experiment. Parameters were optimised by searching the four/five-dimensional grid which is created by ranges of C, γ, the chosen kernel and the SIFT/BoVW dictionary sizes for each imaging modality.

The permutation of these parameters which returns the maximum accuracy determines the optimal model. C is a penalty parameter for misclassification while γ is related to the radius of influence of the support vectors that the model selects. The grid search process for parameter optimisation involved several steps:

1. Parameter C was sampled over the range $[2^{-5}, 2^{-4}, ..., 2^{15}]$ while γ was sampled over the range $[2^{15}, 2^{14}, ..., 2^{3}]$. The kernels tested were linear and radial basis function. Other model parameters used the default settings of the package.

2. The parameters given by the dictionary sizes for digital pathology and RCI were sampled over $[50, 75, 100, 200, 300, 500, 1000]$ and $[5, 10, 25, 50, 100, 200, 300]$ respectively. This equated to images being represented by histograms of varying length, equivalent to the number of visual words created via the clustering process of the BoVW dictionary generation.

3. Given the five parameters used for optimisation in the multi-modal imaging approach i.e. digital pathology and RCI, the number of permutations searched is given by the product of the length of each parameter vector. In the case of the single modality model i.e. digital pathology imaging or RCI only, total permutations are given by the product of the length of four parameter value vectors i.e. C, γ, kernel choice and dictionary size. The process of parameter optimisation is discontinuous and attempts to find the global minimum for model error and maximum for model accuracy. It is unlikely that a true global minimum/maximum could be found given that a continuous search over unbounded ranges of the parameters is practically impossible. Additionally, a continuous differentiable function whose derivative exists at each point in the domain and that can be analytically solved is unknown.

4. Each parameter combination was used to derive image histograms of specified size and set SVM parameter values. Five-fold cross validation was used to assess the performance of the model with the metrics sensitivity, specificity, overall accuracy, AUC and the ROC curve being used to interpret results. Accuracy was optimised with the classes for each model being well balanced. Metrics from the cross-validation process were calculated as the mean values over each of the five folds. The probability-like values and categorical predictions obtained from the SVM classifier over each fold were used to form an ROC curve and confusion matrix for the entire dataset. Tables S4 and S5 outline the parameters of the optimised SIFT/BoVW SVM models.

2.12 Classification using Raman spectral data

For comparison with the image-based approaches, classification models were also constructed using median Raman spectra per sample, as described below.

2.13 Calculation of median Raman spectrum

For each Raman image collected, several pre-processing steps were carried out prior to calculation of the median Raman spectrum for each sample. First, in order to remove the image background (i.e. non-sample parts of the image), principal components analysis was applied to each image individually. The principal component (PC) score images were visually assessed, and the score image that best separated the sample from the background was selected. A mask was then created by thresholding that PC score image based on the distribution of pixel intensities in the PC score image histogram. Pixels containing cosmic rays and saturated spectral regions were subsequently removed using the approach described by Dorrepaal et al.124

Briefly, for each spectrum, standard normal variate pretreatment was applied to the spectrum; the difference in intensity between neighboring Raman shifts was calculated and the standard deviation of this ‘difference’ spectrum was calculated. Spectra with a standard deviation greater than the mean +/- 3 times the standard deviation of this value were identified as Cosmic Rays or saturated pixels and removed from the image by masking. Finally, in some image masks, very small regions outside of the core were noticed (possibly due to fragmentation of a core or residue from processing). In order to remove these from the images, all image regions with less than 10 pixels were identified and set to zero in the mask. A composite mask (= background removal + cos-
Algorithmic process for feature extraction and classification for single and multimodal imaging cases. (a) Feature extraction (SIFT descriptors), (b) K-Means clustering yields visual words, (c) Feature quantization to create visual word histograms per image, (d) Classification stage. Figure adapted from [74].
mic ray/saturated pixels + small regions masks) was created and applied to the image. Subsequently the median Raman spectrum was calculated for each image.

2.14 PLS-DA modelling

Partial least squares discriminant analysis was applied to the median Raman spectra of the unstained TMAs for comparison with the multi-modal imaging approach. Models were constructed using untreated Raman spectra and six spectral pretreatments: SNV, 1st derivative Savitzky Golay pretreatment (‘1st der’, window size = 15 points, polynomial order = 3), 2nd derivative Savitzky Golay pretreatment (‘2nd der’, window size = 15 points, polynomial order = 3), combinations of SNV followed by 1st or 2nd derivative pretreatment and multiplicative scatter correction (MSC). In addition, the fluorescence background was removed from the spectra using an exaggerated smoothing (0 order Savitzky Golay smoothing with a window size of 301) and subtracting the smoothed spectrum from the original median Raman spectrum. This pretreatment was then followed by the 6 spectral pretreatments described above. Model parameters such as optimal pre-treatment and number of latent variables were selected by random cross validation on the data from the SIFT sets for non-cancer/cancer discrimination and Gleason grade 3/grade 4 discrimination. For random cross validation, 70% of the spectra were randomly selected for model building and the remaining 30% were used for cross validation (the ‘randperm’ function in MATLAB was used to randomly permute the data). This process was repeated 200 times and the mean accuracy, sensitivity and specificity were calculated for each combination of spectral pre-treatment and number of latent variables. The optimal spectral pretreatment and number of latent variables was selected based on consideration of the mean accuracy, and product of sensitivity and specificity. Subsequently, 5-fold cross validation using the selected parameters was carried out using the same folds as used in the image based models. As described in Section 2.10, the cross-validation was structured such that samples from 5 disjoint sets of patients were used in each fold - this ensured patient independence across folds. Using the selected model parameters, calibration models were then re-built on the combination of the SIFT reference sets and the calibration set for a given fold number, and validated on the corresponding independent patient set. Unless otherwise specified, Raman image processing was carried out using MATLAB (MATLAB R2019a, The MathWorks Ltd) functions written in house and from the image processing toolbox.

3 Results

This study compared the performance of single modality approaches (digital histopathology, Raman chemical imaging (RCI) and median Raman spectra) to a multimodal (RCI + digital pathology) approach in classifying the pathological state of prostate tissue samples using SIFT and a support vector machine (SVM) classifier. A random set of patient’s samples were used as the reference image set. Features from this set were clustered to yield visual words, which were then used to encode images in the classification set. Two binary classification tasks were explored in order to show the competing performance of the single and multi-modal imaging approaches. These tasks were cancer/non-cancer and Gleason grade 3/grade 4 binary classification. Each of these tasks were tested with regard to both the single and multimodal imaging input types. The classification algorithm makes a diagnostic prediction based on the extracted features for each TMA core sample.

3.1 Classification using Raman spectra

Classification results for cancer vs. non-cancer based on PLS-DA models constructed on median Raman spectra are presented in the Supplementary material. The optimal PLS-DA model parameters (based on maximum product of sensitivity and specificity) were selected as no pretreatment followed by 2nd derivative Savitzky Golay pre-processing and a PLS-DA model with 9 latent variables. PLS-DA models using these parameters were then built and cross validated on the 5 folds used in the imaging models.

The resultant confusion matrix is shown in Figure 8. The accuracy of this approach was 58.3%, with a sensitivity of 0.62 and a specificity of 0.54.

As for the PLS-DA models for Gleason grade 3/grade 4 classification, the product of mean sensitivity and specificity calculated over 200 random splits of the reference image set (shown in Figure S2) indicated optimal PLS-DA model parameters to be fluorescence removal followed by 1st derivative preprocessing and a PLS-DA model with 4 latent variables. PLS-DA models using these parameters were then built and cross validated on the same 5 folds used for the imaging models. The resultant confusion matrix is shown in Table S2. The accuracy of this approach was 42%, with a sensitivity of 0.33 and a specificity of 0.49.

These results show that the use of median Raman spectra alone produces relatively poor classification models, suggesting the need to consider the image related features in subsequent modelling. Therefore, in addition to a representative median spectra approach, we investigated a method based on the greyscale Raman chemical image of the tissue sample, calculated using the mean spectral value per pixel. This approach allowed the incorporation of both biochemical data from pixel spectra and structural and morphological information via the spatial distribution of pixel intensities.
3.2 Classification using Raman Chemical Imaging

Using RCI images, a 5-fold cross-validated model was constructed based on images encoded by a random reference set as detailed in Section 2.8 and Table 2. The binary non-cancer/cancer classifier yielded a sensitivity and specificity of \(72.5\% \pm 0.1\%\) and \(69.0\% \pm 0.1\%\) respectively (Figure 9) with a reported accuracy of \(70.3\% \pm 2.8\%\) and AUC of \(0.707 \pm 0.038\).

![Fig. 9](image)

**Fig. 9** Confusion matrix for classification of cancer vs. non-cancer samples using RCI imaging alone (left) with confusion ball graphic of specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity and specificity are mean values over cross-validation folds.

Gleason grade 3 and 4 classification was then investigated using RCI imaging. Similarly, a 5-fold cross-validated model with images encoded by a random reference set was investigated. The model achieved an accuracy of \(68.0\% \pm 20.0\%\), sensitivity of \(72.7\% \pm 22.5\%\) and specificity of \(68.0\% \pm 29.5\%\) (Figure 10). The AUC was found to be \(0.750 \pm 0.192\). Results in this section were mean values per fold.

![Fig. 10](image)

**Fig. 10** Confusion matrix for classification of Gleason grades 3 and 4 samples using RCI imaging alone (left) with confusion ball graphic of specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity and specificity are mean values over cross-validation folds.

3.3 Classification using Digital Pathology Imaging

Using digital pathology images, a 5-fold cross-validated model was constructed based on images encoded by a random reference set. The binary classification of cancer and non-cancer samples yielded a sensitivity and specificity of \(81.9\% \pm 15.3\%\) and \(80.0\% \pm 16.4\%\) respectively (Figure 11) with a reported accuracy of \(82.3\% \pm 6.0\%\) and AUC of \(0.878 \pm 0.058\).

![Fig. 11](image)

**Fig. 11** Confusion matrix for classification of cancer vs. non-cancer samples using digital pathology imaging alone (left) with confusion ball graphic of specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity and specificity are mean values over cross-validation folds.

The binary classification of Gleason grade 3 and 4 was investigated using only features from digital pathology images. Applying a 5-fold cross-validated model with images encoded by a random reference set, an accuracy of \(74.1\% \pm 9.3\%\), sensitivity of \(54.1\% \pm 30.0\%\) and specificity of \(84.7\% \pm 3.0\%\) was achieved (Figure 12). AUC was given as \(0.731 \pm 0.211\). Results in this section were mean values per fold.

![Fig. 12](image)

**Fig. 12** Confusion matrix for classification of Gleason grades 3 and 4 samples using digital pathology imaging alone (left) with confusion ball graphic of specificity and sensitivity (right). Confusion matrix based on pooled predictions over 5-fold cross-validation. Sensitivity and specificity are mean values over cross-validation folds.

3.4 Classification using Multimodal Imaging

The multimodal model of digital pathology and Raman imaging applied to classification of non-cancer/cancer samples yielded a sensitivity and specificity of \(78.4\% \pm 18.7\%\) and \(81.6\% \pm 6.9\%\) respectively on 5-fold cross-validation with a random reference set for encoding classification images (Figure 13). Accuracy was found to be \(80.8\% \pm 7.7\%\) with AUC being \(0.845 \pm 0.065\).
In the case of Gleason grade 3 and 4 classification, a model utilising features from both digital pathology and Raman imaging modalities gave an accuracy, sensitivity and specificity of 82.8% ± 18.1%, 73.8% ± 27.3% and 88.1% ± 16.8% respectively for 5-fold cross-validation, with images encoded by a random reference set (Figure 14). The AUC was 0.858 ± 0.186. Results in this section were mean values per fold.

3.5 ROC Curves Comparison

For the binary classification of cancer and non-cancer samples, the ROC curves for Raman chemical imaging, digital pathology and the multimodal combination of both imaging modalities can be seen in Figure 15. The receiver operator characteristic (ROC) curves indicate that models based on the single modality of digital pathology and multimodal combination of digital pathology and Raman chemical imaging exhibit closely matched diagnostic ability.

From observation of the ROC curve in Figure 15, it can be seen that the digital pathology model (red curve) generally achieves slightly better sensitivity than the multimodal model with the exception of the region where specificity ranges between 80% and 90%. RCI does exhibit some ability to differentiate sample classes but appears to add little when combined with the digital pathology approach for the non-cancer/cancer task.

3.6 Multiple Reference Set Results and T-test

Paired t-tests were conducted to ascertain if there was a significant difference in the AUC values of the digital pathology and multimodal models presented in the preceding sections. The AUC values were those calculated on the validation sets of the 5-fold cross-validation of both models. No significant difference was observed between the digital pathology and multimodal approaches for the binary non-cancer/cancer classification task. The mean AUC difference (M=0.033, SD=0.064, N=5) was not significantly greater than zero, t(5)=2.776, two tail p=0.318. However,
in the case of Gleason grade 3/grade 4 classification, the fusion of digital pathology and RCI showed potential for improved diagnostic performance for prostate cancer severity. The mean AUC difference (M=0.127, SD=0.059, N=5) was significantly greater than zero, t(5)=2.776, two tail p=0.009, providing evidence that the model is effective in improving binary classification of Gleason grade 3 and 4 prostate cancer. The 95% confidence interval about the mean difference is (0.054, 0.201).

Results pertaining to the Gleason grade 3/grade 4 classification task where the average performances were reported over ten models (each model with different random patient groupings for the reference set and cross-validation folds) are contained in Table 3.

Table 3 Average results of 5-fold cross-validation over 10 models (randomly selected patient groups for reference set and cross-validation folds) for Gleason grade 3/4 classification across digital pathology (DP), Raman Chemical Imaging (RCI) and multimodal approaches (DP + RCI)

| Imaging Modality | Sensitivity | Specificity | AUC  | False Negative Rate |
|------------------|-------------|-------------|------|---------------------|
| RCI              | 63.3%       | 77.8%       | 0.714| 36.7%               |
| DP               | 63.5%       | 84.9%       | 0.764| 36.5%               |
| Multimodal       | 74.9%       | 83.4%       | 0.826| 25.1%               |

It was noted that there was generally a reduced advantage between the multimodal and digital pathology model for Gleason grade 3 and 4 classification when taking the average results of 10 different configurations of reference set and cross-validation folds (Table 3), as compared to results using a single reference set in Sections 3.3 and 3.4.

4 Discussion

Integration of Raman spectroscopy with other modalities can lead to significantly improved performance of a combined multimodal measurement in comparison to what either modality could achieve alone. Raman spectroscopy and its derivations are valuable for a range of clinical applications in the field of medicine including prostate cancer. To date, few studies have investigated the value in combining Raman Chemical Imaging (RCI) with other modalities. This work explores the integration of digital histopathology with RCI for the classification of prostate cancer tissue samples. We investigated whether a machine learning algorithm could perform better using this multimodal approach in comparison to utilising a range of single imaging inputs. Sample labels defined from pathologist examination of H&E images were applied to the corresponding RCI images.

The developed machine learning algorithm predicts the pathological grade of the sample based on extracted image features. Two binary classification models were developed: the first classifies tissue samples as cancer or non-cancer with the second differentiating malignant samples as Gleason grade 3 or 4. The study compared performances of models utilizing the single modalities of digital histopathology, RCI and median Raman spectra in addition to the multimodal combination of digital histopathology and RCI. It was observed that the multimodal imaging approach outperformed single imaging for the differentiation of Gleason grades 3 and 4. The best binary non-cancer/cancer models were those utilising digital pathology images and multimodal digital pathology/RCI images, with both achieving similar performance. Given that binary non-cancer/cancer diagnosis is a simpler task than differentiation of Gleason grade 3 and 4, there may have been enough information in the histopathological sample images to preclude any advantage from multimodal imaging. However, as pathologists can find it more challenging to differentiate between Gleason grade 3 and 4, the additional sub-visual information from the unstained RCI images may explain the improved diagnostic performance observed in this case.

Differentiation of Gleason grades 3 and 4 is a clinically relevant problem with a potentially high cost of error in assessment of these patterns. Where the discovery of a Gleason pattern 4 on follow-up biopsy would prompt the termination of active surveillance for a patient, misclassification of Gleason patterns 3 and 4 would have a major therapeutic impact. In the case of Gleason grade 3 and 4 classification, a paired t-test indicated that the mean difference in area under the ROC curve for cross-validation fold values was significantly greater than zero where P<0.05 was considered statistically significant. This observation implies that there are properties and features of the RCI image that augment the information derived from histopathological images. This may be a reasonable assumption given that RCI produces a biochemical map of the sample with the intensities of the mean Raman image deriving directly from the spectral contributions of various biological components such as DNA, RNA and the extracellular matrix. Additionally, the spatial property of RCI contributes morphological information by accounting for changes in intensities within local neighbourhoods and thus identifying structural features within the sample.

A further finding of note is the relatively good performance of the Gleason grade 3/4 classification model that used RCI imaging only as input. This suggests potential to use mean Raman images for Gleason grade 3/4 diagnosis. Less processing (such as chemical staining of samples) would be required with a few spectral points needed to form the chemical image. A lower cost/relatively rapid Raman-based device could potentially be constructed using this principle.

In this study, limited samples precluded the use of a separate test set in addition to the cross-validation approach used. The classification algorithms would benefit from acquisition of more data with the increased training likely leading to greater robustness and improved predictive power. The study is a preliminary validation; to improve chances of developing a clinically useful diagnostic classifier, the proposed multimodal imaging model should be trained on samples from a significant cohort of patients and evaluated on data from a range of hospitals and laboratories. This would introduce greater variation and better reflect real world data that the diagnostic classifier would encounter.

The primary stages of the model were image preprocessing, feature extraction and classification. Histogram equalization, SIFT with visual BoW and an SVM classifier were utilized to propose a model that could serve in diagnosis of prostate cancer pathological grades within a digital histopathological and Raman chemical imaging workflow. Support vector machines are commonly
used due to their computational efficiency and robustness as they minimize over-fitting by adding structural constraints. Despite these properties and the use of stratified K-fold cross validation, additional validation on larger datasets and the use of separate test sets are required to further assess the generalizability of our models. Other limitations of the study include the use of multiple samples per patient. To ensure patient independence in the modelling process, samples from disjoint sets of patients were used for the reference and cross-validation folds. In our study, labelling is done by a single pathologist, which may carry greater misclassification risk versus having multiple labelers. The employment of a consensus pathology approach should strengthen the ground truth.

With acquisition of extended data, future work would include the application of deep learning and transfer learning to assess RCI augmentation of digital pathology and the use of methods that facilitate some degree of explainable artificial intelligence so that the model diagnostic decision process could be interrogated. The addition of a tumour segmentation step is worth exploring as many studies benefit from guiding the feature extraction process to specific areas of the image.

5 Conclusion

Multimodal image analysis is an important area of biomedical science. The combination of information from multiple sources can lead to improved diagnosis and treatment strategies, directly benefiting the patient's quality of life and prognosis. This work demonstrates that the fusion of digital histopathology and Raman chemical imaging modalities has potential to improve the diagnostic performance for prostate cancer by integrating both morphological and biochemical information across both data sources. Comparative results across the single and multimodal approaches to non-cancer/cancer and Gleason grade 3/grade 4 differentiation indicates that a multimodal approach does not improve tumour identification but is useful for the more challenging task of tumour severity identification.

The reasonable performance of approaches based on Raman chemical imaging only, indicates potential for a cost-effective and rapid means of assessing prostate cancer grades without requiring staining. However, while this study suggests that the integration of digital histopathology and Raman chemical imaging is a promising research method for the critical and challenging diagnosis of Gleason grade 3 and 4, the observed modest improvement should be considered in the context of the current cost and time required for Raman chemical imaging.

6 Author Contributions

AG, WMG, RWGW and SPF contributed to experimental planning and design. EK was involved in proposal development and academic supervision. NAA designed and developed the experimental methodology for TMA Raman mapping acquisition and production of chemical images, described the experimental methodology, developed a protocol for sample preparation and curated data. AR contributed via protocol development and preparation for H&E samples and data interpretation, while AON was involved in tissue sample and TMA preparation. TM acquired and processed Raman spectra and images. TD carried out image processing, conducted formal analysis through development of the machine learning methodology and classification models and was involved in overall manuscript conceptualisation and writing. CA annotated and labelled digital histopathology TMA core samples. SMK advised on machine learning and classification model development and was involved in academic supervision. PJ contributed to solution engineering and design. AG conducted formal analysis of Raman spectra models and contributed to manuscript writing. SPF, WMG, RWGW, SMK, PJ and AG reviewed and edited the final manuscript.

7 Conflicts of interest

WMG is co-founder, shareholder and Chief Scientific Officer of OncoMark Limited, as well as Scientific Advisory Board member for Carrick Therapeutics.

8 Acknowledgements

This research has been funded by the Irish Health Research Board (Grant Number HRA-POR-2015-1078), with additional support from the Science Foundation Ireland Investigator Programme OPTi-PREDICT (grant code 15/IA/3104); and the Science Foundation Ireland Strategic Partnership Programme Precision Oncology Ireland POI (grant code 18/SPP/3522). Funding for the Irish Prostate Cancer Research Consortium tissue samples was from Science Foundation Ireland, Grant number: TRA/2010/18; Irish Cancer Society, Grant number: PCI11WAT; Health Research Board, Grant number: TRA/2010/18; Welcome Trust-HRB Dublin Centre for Clinical Research.

Notes and references

1 B. Stewart, C. Wild, I. A. for Research on Cancer et al., WHO.(2014) World Cancer Report 2014, 2016.
2 R. L. Siegel, K. D. Miller and A. Jemal, CA: a cancer journal for clinicians, 2020, 70, 7–30.
3 P. A. Humphrey et al., Prostate pathology, American Society for Clinical Pathology Chicago, 2003.
4 D. J. Lomas and H. U. Ahmed, Nature Reviews Clinical Oncology, 2020, 1–10.
5 D. F. Gleason and G. T. Mellinger, The Journal of urology, 1974, 111, 58–64.
6 A. BenTaieb and G. Hamarneh, IEEE transactions on medical imaging, 2017, 37, 792–802.
7 H. O. Lyon, A. De Leenheer, R. Horobin, W. Lambert, E. Schulte, B. Van Liedekerke and D. Wittekind, The Histochemical Journal, 1994, 26, 533–544.
8 P. Leo, R. Elliott, N. N. Shih, S. Gupta, M. Feldman and A. Madabhushi, Scientific reports, 2018, 8, 1–13.
9 W. C. Allsbrook Jr, K. A. Mangold, M. H. Johnson, R. B. Lane, C. G. Lane and J. I. Epstein, Human pathology, 2001, 32, 81–88.
10 A. D. Borowsky, E. F. Glassy, W. D. Wallace, N. S. Kallichanda, C. A. Behling, D. V. Miller, H. N. Oswal, R. M. Feddersen, O. R. Bakhtar, A. E. Mendoza et al., Archives of Pathology & Laboratory Medicine, 2020.
11 C. Mosquera-Lopez, S. Agaian, A. Velez-Hoyos and I. Thompson, *IEEE reviews in biomedical engineering*, 2014, 8, 98–113.
12 H. Irshad, A. Veillard, L. Roux and D. Raccoceau, *IEEE reviews in biomedical engineering*, 2013, 7, 97–114.
13 A. Madabhushi and G. Lee, *Image analysis and machine learning in digital pathology: Challenges and opportunities*, 2016.
14 J. Dybas, K. M. Marzec, M. Z. Pacia, K. Kochan, K. Czamara, K. Chrabaszcz, E. Staniszewska-Slezak, K. Malek, M. Baranska and A. Kaczor, *TrAC Trends in Analytical Chemistry*, 2016, 85, 117–127.
15 M. J. Baker, H. J. Byrne, J. Chalmers, P. Gardner, R. Goodacre, A. Henderson, S. G. Kazarian, F. L. Martin, J. Moger, N. Stone et al., *Analyst*, 2018, 143, 1735–1757.
16 C. Krafft, M. Schmitt, I. W. Schie, D. Cialla-May, C. Matthäus, T. Bocklitz and J. Popp, *Angewandte Chemie International Edition*, 2017, 56, 4392–4430.
17 M. Roman, T. P. Wrobel, A. Panek, E. Efeoglu, J. Wiltowska-Zuber, C. Paluszkiewicz, H. J. Byrne and W. M. Kwiatek, *Scientific reports*, 2019, 9, 1–13.
18 Z. Movasaghi, S. Rehman and I. U. Rehman, *Applied Spectroscopy Reviews*, 2007, 42, 493–541.
19 M. Chowdary, K. K. Kumar, K. Thakur, A. Anand, J. Kurien, C. M. Krishna and S. Mathew, *Photomedicine and laser surgery*, 2007, 25, 269–274.
20 B. Brozek-Pluska, J. Musial, R. Kordek and H. Abramczyk, *International journal of molecular sciences*, 2019, 20, 3398.
21 M. Gniadecka, P. A. Philipsen, S. Wessel, R. Gniadecki, H. C. Wulf, S. Sigurðsson, O. F. Nielsen, D. H. Christensen, J. Hercock, H. Zeng, et al., *Journal of investigative dermatology*, 2018, 143, 2179–2186.
22 A. S. Haka, K. E. Shafer-Peltier, M. Fitzmaurice, J. Crowe, R. R. Dasari and M. S. Feld, *Proceedings of the National Academy of Sciences*, 2005, 102, 12371–12376.
23 Z. Huang, A. McWilliams, H. Lui, D. I. McLean, S. Lam and H. Zeng, *International journal of cancer*, 2003, 107, 1047–1052.
24 F. M. Lyng, E. O. Faoláin, J. Conroy, A. Meade, P. Knief, B. Duffy, M. Hunter, J. Byrne, P. Kelehan and H. Byrne, *Experimental and molecular pathology*, 2007, 82, 121–129.
25 P. Crow, N. Stone, C. Kendall, J. Uff, J. Farmer, H. Barr and M. Wright, *British journal of cancer*, 2003, 89, 106–108.
26 S. Devpura, J. S. Thakur, F. H. Sarkar, W. A. Saku, V. M. Naik and R. Naik, *Vibrational Spectroscopy*, 2010, 53, 227–232.
27 M. Tollefson, J. Magera, T. Sebo, J. Cohen, A. Drauch, J. Maier and I. Frank, *BJU international*, 2010, 106, 484–488.
28 R. E. Kast, S. C. Tucker, K. Killian, M. Trexler, K. V. Honn and G. W. Auner, *Cancer and Metastasis Reviews*, 2014, 33, 673–693.
29 A. Samiei, R. Miller, J. Cohen, H. Gomer, S. Stewart and P. Treado, *CANCER RESEARCH*, 2018, pp. 121–122.
30 P. Crow, A. Molckovsky, N. Stone, J. Uff, B. Wilson and L.-M. WongKeeSong, *Urology*, 2005, 65, 1126–1130.
31 S. Li, Y. Zhang, J. Xu, L. Li, Q. Zeng, L. Lin, Z. Guo, Z. Liu, H. Xiong and S. Liu, *Applied Physics Letters*, 2014, 105, 091104.
32 L. Wang, D. He, J. Zeng, Z. Fuan, Q. Dang, X. Wang, J. Wang, L. Huang, P. Cao, G. Zhang et al., *Journal of biomedical optics*, 2013, 18, 087001.
33 P. Crow, B. Barrass, C. Kendall, M. Hart-Prieto, M. Wright, R. Persad and N. Stone, *British journal of cancer*, 2005, 92, 2166–2170.
34 G. Del Mistro, S. Cervo, E. Mansutti, R. Spizzo, A. Colombatti, P. Belmonte, R. Zucconelli, A. Steffan, V. Sergio and A. Bonifacio, *Analytical and Bioanalytical Chemistry*, 2015, 407, 3271–3275.
35 J. Du, W. Li, K. Lu and B. Xiao, *Neurocomputing*, 2016, 215, 3–20.
36 A. P. James and B. V. Dasarathy, *Information fusion*, 2014, 19, 4–19.
37 J. T. Kwak, S. M. Hewitt, S. Sinha and R. Bhargava, *BMC cancer*, 2011, 11, 62.
38 E. Rodner, T. Bocklitz, F. von Eggeling, G. Ernst, O. Cherneveskaya, J. Popp, J. Denzler and O. Guntinas-Lichius, *Head & Neck*, 2019, 41, 116–121.
39 C. A. Patil, N. Bosschaart, M. D. Keller, T. G. van Leeuwen and A. Mahadevan-Jansen, *Optics letters*, 2008, 33, 1135–1137.
40 P. C. Ashok, B. B. Praveen, N. Bellini, A. Riches, K. Dhokalia and C. S. Herrington, *Biomedical optics express*, 2013, 4, 2179–2186.
41 Y. Yuan, H. Failmezger, O. M. Rueda, H. R. Ali, S. Gräf, S.-F. Chin, R. F. Schwarz, C. Curtis, M. J. Dunning, H. Bardwell et al., *Science translational medicine*, 2012, 4, 157ra143–157ra143.
42 T. H. Nguyen, S. Sridharan, V. Macias, A. Kajdacsy-Balla, J. Melamed, M. N. Do and G. Popescu, *Journal of biomedical optics*, 2017, 22, 036015.
43 G. Lee, R. Sparks, S. Ali, N. N. Shih, M. D. Feldman, E. Spangler, T. Rebbeck, J. E. Tomaszewski and A. Madabhushi, *PloS one*, 2014, 9, e97954.
44 M. Veta, R. Korneegoor, A. Huisman, A. H. Verschuur-Maes, M. A. Viergever, J. P. Pluim and P. J. Van Diest, *Modern pathology*, 2012, 25, 1559–1565.
45 S. Doyle, M. Hwang, K. Shah, A. Madabhushi, M. Feldman and J. Tomaszewski, 2007 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, 2007, pp. 1284–1287.
46 R. Sparks and A. Madabhushi, *Medical image analysis*, 2013, 17, 997–1009.
47 N. Linder, J. Konst, R. Turkki, E. Rahtu, M. Lundin, S. Nordling, C. Haglund, T. Ahonen, M. Pietikäinen and J. Lundin, *Diagnostic pathology*, 2012, 7, 22.
48 K. Jafari-Khouzani and H. Soltanian-Zadeh, *IEEE Transactions on Biomedical Engineering*, 2003, 50, 697–704.
49 F. M. Sanghavi and S. S. Agaian, Mobile Multimedia/Image Processing, Security, and Applications 2016, p. 98690T.
50 D. G. Lowe, *International journal of computer vision*, 2004, 60, 91–110.
51 D. Bychkov, N. Linder, R. Turkki, S. Nordling, P. E. Kova-
nen, C. Verrill, M. Wallander, M. Lundin, C. Haglund and J. Lundin, Scientific reports, 2018, 8, 1–11.

52 M. G. Ertosun and D. L. Rubin, AMIA Annual Symposium Proceedings, 2015, p. 1899.

53 C.-K. Shie, C.-H. Chuang, C.-N. Chou, M.-H. Wu and E. Y. Chang, 2015 37th annual international conference of the IEEE Engineering in Medicine and Biology Society (EMBC), 2015, pp. 711–714.

54 S. Weng, X. Xu, J. Li and S. T. Wong, Journal of biomedical optics, 2017, 22, 106017.

55 A. Esteva, B. Kuprel, R. A. Novoa, J. Ko, S. M. Swetter, H. M. Blau and S. Thrun, nature, 2017, 542, 115–118.

56 E. Ribeiro, A. Uhl, G. Wimmer and M. Häfner, Computational and mathematical methods in medicine, 2016, 2016, year.

57 J. Chi, E. Walia, P. Babyn, J. Wang, G. Groot and M. Eramian, Journal of digital imaging, 2017, 30, 477–486.

58 H.-C. Shin, H. R. Roth, M. Gao, L. Lu, Z. Xu, I. Nogues, J. Yao, D. Mollura and R. M. Summers, IEEE transactions on medical imaging, 2016, 35, 1285–1298.

59 J. Ishioka, Y. Matsuoka, S. Uehara, Y. Yasuda, T. Kijima, S. Yoshida, M. Yokoyama, K. Saito, K. Kihara, N. Numao et al., BJU international, 2018, 122, 411–417.

60 E. Arvaniti, K. S. Fricker, M. Moret, N. Rupp, T. Hermanns, C. Fankhauser, N. Wey, P. J. Wild, J. H. Rueschoff and M. Claassen, Scientific reports, 2018, 8, 1–11.

61 G. Litjens, C. I. Sánchez, N. Timofeeva, M. Hermsen, I. Nagtegaal, I. Kovacs, C. Hulsbergen-Van De Kaa, P. Bult, B. Van Ginneken and J. Van Der Laak, Scientific reports, 2016, 6, 26286.

62 Y. Song, Y.-D. Zhang, X. Yan, H. Liu, M. Zhou, B. Hu and G. Yang, Journal of Magnetic Resonance Imaging, 2018, 48, 1570–1577.

63 N. O’Mahony, S. Campbell, A. Carvalho, S. Harapanahalli, G. V. Hernandez, L. Kpalkova, D. Riordan and J. Walsh, Science and Information Conference, 2019, pp. 128–144.

64 X. Wang, W. Yang, J. Weinreb, J. Han, Q. Li, X. Kong, Y. Yan, Z. Ke, B. Luo, T. Liu et al., Scientific reports, 2017, 7, 1–8.

65 O. Russakovsky, J. Deng, H. Su, J. Krause, S. Satheesh, S. Ma, Z. Huang, A. Karpathy, A. Khosla, M. Bernstein et al., International journal of computer vision, 2015, 115, 211–252.

66 K. J. Breen, A. O’Neill, L. Murphy, Y. Fan, S. Boyce, N. Fitzgerald, E. Dorris, L. Brady, S. P. Finn, B. D. Hayes et al., The Prostate, 2017, 77, 1288–1300.

67 S. M. Hospital, http://www.stmichaelshospital.com/research/facilities/images/histology-methods-hematoxylin-eosin-staining-manual-protocol.pdf (Hematoxylin and Eosin (H&E) Staining – Manual Protocol).

68 A. Rahman, C. Jahangir, S. M. Lynch, N. Alattar, C. Aura, N. Russell, F. Lanigan and W. M. Gallagher, Expert Review of Molecular Diagnostics, 2020, 1–11.

69 T. Lindeberg, 2012.

70 G. Csurka, C. Dance, L. Fan, J. Willamowski and C. Bray, Workshop on statistical learning in computer vision, ECCV, 2004, pp. 1–2.

71 G. Csurka and M. Humenberger, arXiv preprint arXiv:1807.10254, 2018, 2, year.

72 J. Yang, Y.-G. Jiang, A. G. Hauptmann and C.-W. Ngo, Proceedings of the international workshop on Workshop on multimedia information retrieval, 2007, pp. 197–206.

73 D. Lin, Z. Lin, J. Cao, R. Velmurugan, E. S. Ward and R. J. Ober, PloS one, 2019, 14, e0218931.

74 H. K. Suh, J. W. Hofstee, J. Isselmuiden and E. J. van Henten, Biosystems Engineering, 2018, 166, 210–226.

75 F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg et al., The Journal of machine Learning research, 2011, 12, 2825–2830.

76 C.-W. Hsu, C.-C. Chang, C.-J. Lin et al., A practical guide to support vector classification, 2003.

77 R. Dorrepaal, C. Malegori and A. Gowen, Journal of Near Infrared Spectroscopy, 2016, 24, 89–107.

78 N. K. Das, Y. Dai, P. Liu, C. Hu, L. Tong, X. Chen and Z. J. Smith, Sensors, 2017, 17, 1592.

79 J. K. McKenney, J. Simko, M. Bonham, L. D. True, D. Troyer, S. Hawley, L. F. Newcomb, L. Fazli, L. P. Kunju, M. M. Nicolas et al., The Journal of urology, 2011, 186, 465–469.
Electronic Supplementary Information

Supplementary Figures

Fig. S17 Product of sensitivity and specificity for PLS-DA models constructed on median Raman spectra for non-cancer/cancer classification. Values shown are the mean calculated over 200 random splits of the reference image set. Models were constructed using untreated Raman spectra and six spectral pretreatments: standard normal variate pre-processing (SNV), 1st derivative Savitzky Golay pretreatment (‘1st der’, window size = 15 points, polynomial order = 3), 2nd derivative Savitzky Golay pretreatment (‘2nd der’, window size = 15 points, polynomial order = 3), combinations of SNV followed by 1st or 2nd derivative pretreatment and multiplicative scatter correction (MSC). The optimal PLS-DA model parameters were selected as no pretreatment followed by 2nd derivative preprocessing and a PLS-DA model with 9 latent variables. * 9 LV SG2 model
Fig. S18 Product of sensitivity and specificity for PLS-DA models constructed on median Raman spectra for Gleason grade 3/4 Gleason grade 4. Values shown are the mean calculated over 200 random splits of the reference image set. Models were constructed using untreated Raman spectra and six spectral pretreatments: standard normal variate pre-processing (SNV), 1st derivative Savitzky Golay pretreatment (’1st der’, window size = 15 points, polynomial order = 3), 2nd derivative Savitzky Golay pretreatment (’2nd der’, window size = 15 points, polynomial order = 3), combinations of SNV followed by 1st or 2nd derivative pretreatment and multiplicative scatter correction (MSC). The optimal PLS-DA model parameters were selected as fluorescence removal followed by 1st derivative preprocessing and a PLS-DA model with 4 latent variables.
## Supplementary Tables

**Table S4** Confusion matrix for 9 latent variable PLS-DA model constructed on median Raman spectra (no pretreatment followed by 2nd derivative preprocessing) for Non-Cancer (NC) /Cancer (C) classification using 5 fold cross validation

|          | Predicted NC | Predicted C |
|----------|--------------|-------------|
| Actual NC| 32           | 26          |
| Actual C | 27           | 42          |

**Table S5** Confusion matrix for 4 latent variable PLS-DA models constructed on median Raman spectra (pretreated by fluorescence removal followed by 1st derivative preprocessing) for Gleason Grade 3/ Gleason Grade 4 (G3/G4) classification using 5 fold cross validation

|          | Predicted G3 | Predicted G4 |
|----------|--------------|--------------|
| Actual G3| 19           | 20           |
| Actual G4| 20           | 10           |

**Table S6** Details of non-cancer/cancer (NC/C) and Gleason grade 3/grade 4 (G3/G4) models including diagnosis, modalities and number of reference sets. 5-fold cross-validation was used, which incorporated samples from disjoint groups of patients.

| Model No. | Diagnosis | Imaging Modality | No. of Reference Sets |
|-----------|-----------|------------------|-----------------------|
| 1         | NC/C      | DP               | 1                     |
| 2         |           | RCI              | 1                     |
| 3         | G3/G4     | DP+RCI           | 1                     |
| 4         |           | DP               | 1                     |
| 5         |           | RCI              | 1                     |
| 6         |           | DP+RCI           | 1                     |
| 7         |           | DP               | 10                    |
| 8         |           | RCI              | 10                    |
| 9         |           | DP+RCI           | 10                    |
### Table S7

Parameters pertaining to optimal SIFT/BoVW/SVM classifiers that used samples from a single randomly selected set of patients as a reference set. Diagnostic tasks are non-cancer/cancer (NC/C) and Gleason grade 3/grade 4 (G3/G4) with digital pathology (DP), Raman Chemical Imaging (RCI) and multimodal (DP+RCI) imaging modalities.

| Diagnosis | Imaging Modality | Dictionary Size 1 | Dictionary Size 2 | C   | γ   | Kernel |
|-----------|------------------|-------------------|-------------------|-----|-----|--------|
| NC/C      | DP               | 300               |                    | 2^11| 2^6 | rbf    |
|           | RCI              | 50                |                    | 2^8 | 2   | rbf    |
|           | DP+RCI           | 300               | 10                | 2^12| 2^1 | rbf    |
| G3/G4     | DP               | 200               |                    | 2^7 | 2^3 | rbf    |
|           | RCI              | 5                 |                    | 2^13| 2^3 | rbf    |
|           | DP+RCI           | 300               | 5                 | 2^8 | 2^2 | rbf    |

### Table S8

Parameters pertaining to optimal SIFT/BoVW/SVM classifiers. Each imaging modality was investigated using results from 10 different models, each using different sets of samples for reference images. The diagnostic task is Gleason grade 3/grade 4 (G3/G4) differentiation with digital pathology (DP), Raman Chemical Imaging (RCI) and multimodal (DP+RCI) imaging modalities.

| Imaging Modality | Reference Set No. | Dictionary Size 1 | Dictionary Size 2 | C   | γ   | Kernel |
|------------------|-------------------|-------------------|-------------------|-----|-----|--------|
| DP               | 1                 | 100               |                    | 2^12| 2^6 | rbf    |
|                  | 2                 | 500               |                    | 2^8 | 2^1 | rbf    |
|                  | 3                 | 500               |                    | 2^9 | 2^2 | rbf    |
|                  | 4                 | 1000              |                    | 2^7 | 2^3 | rbf    |
|                  | 5                 | 50                |                    | 2^14| 2^1 | rbf    |
|                  | 6                 | 500               |                    | 2^9 | 2^1 | rbf    |
|                  | 7                 | 100               |                    | 2^12| 2^9 | rbf    |
|                  | 8                 | 200               |                    | 2^7 | 2^1 | rbf    |
|                  | 9                 | 1000              |                    | 2^11|     |        |
|                  | 10                | 500               |                    | 2^9 | 2^1 | rbf    |
| RCI              | 1                 | 10                |                    | 2^4 | 2^3 | rbf    |
|                  | 2                 | 25                |                    | 2^9 | 2^1 | rbf    |
|                  | 3                 | 5                 |                    | 2^2 | 2^1 | rbf    |
|                  | 4                 | 10                |                    | 2^15| 2^1 | rbf    |
|                  | 5                 | 5                 |                    | 2^5 | 2^1 | rbf    |
|                  | 6                 | 1000              |                    | 2^8 | 2^2 | rbf    |
|                  | 7                 | 25                |                    | 2^2 | 2^2 | rbf    |
|                  | 8                 | 5                 |                    | 2^13| 2^1 | rbf    |
|                  | 9                 | 25                |                    | 2^6 | 2^1 | rbf    |
| DP+RCI           | 1                 | 50                |                    | 2^14| 2^1 | rbf    |
|                  | 2                 | 200               |                    | 2^8 | 2^1 | rbf    |
|                  | 3                 | 100               | 5                 | 2^8 | 2^1 | rbf    |
|                  | 4                 | 1000              | 10                | 2^12| 2^2 | rbf    |
|                  | 5                 | 50                | 5                 | 2^12| 2^2 | rbf    |
|                  | 6                 | 200               | 5                 | 2^11| 2^1 | rbf    |
|                  | 7                 | 50                | 50                | 2^8 | 2^1 | rbf    |
|                  | 8                 | 300               | 5                 | 2^8 | 2^1 | rbf    |
|                  | 9                 | 1000              | 5                 | 2^9 | 2^2 | rbf    |
|                  | 10                | 75                | 5                 | 2^14| 2^3 | rbf    |